LRT Capital Management LLC Sells 12,870 Shares of Cencora, Inc. $COR

LRT Capital Management LLC lessened its position in Cencora, Inc. (NYSE:COR) by 88.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,752 shares of the company’s stock after selling 12,870 shares during the quarter. LRT Capital Management LLC’s holdings in Cencora were worth $548,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Laird Norton Wetherby Wealth Management LLC lifted its position in Cencora by 3.1% during the third quarter. Laird Norton Wetherby Wealth Management LLC now owns 5,787 shares of the company’s stock valued at $1,809,000 after buying an additional 176 shares during the period. Larson Financial Group LLC grew its position in shares of Cencora by 16.0% in the 3rd quarter. Larson Financial Group LLC now owns 3,215 shares of the company’s stock worth $1,005,000 after buying an additional 444 shares during the period. Lido Advisors LLC increased its stake in shares of Cencora by 10.3% in the 3rd quarter. Lido Advisors LLC now owns 8,778 shares of the company’s stock worth $2,744,000 after acquiring an additional 822 shares in the last quarter. Integrated Wealth Concepts LLC increased its stake in shares of Cencora by 17.0% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 8,369 shares of the company’s stock worth $2,616,000 after acquiring an additional 1,219 shares in the last quarter. Finally, Humankind Investments LLC boosted its stake in Cencora by 2.7% during the third quarter. Humankind Investments LLC now owns 1,918 shares of the company’s stock worth $599,000 after acquiring an additional 51 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 15,220 shares of company stock valued at $5,282,867. Corporate insiders own 0.38% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Barclays upped their price objective on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. JPMorgan Chase & Co. upped their price target on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Finally, Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $399.00.

Cencora Stock Down 1.1%

Shares of Cencora stock opened at $345.98 on Tuesday. The company has a 50-day simple moving average of $355.68 and a two-hundred day simple moving average of $339.20. The stock has a market capitalization of $67.30 billion, a PE ratio of 41.58, a price-to-earnings-growth ratio of 1.63 and a beta of 0.68. Cencora, Inc. has a 52-week low of $255.76 and a 52-week high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same quarter last year, the firm earned $3.73 earnings per share. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.